Uzuncakmak Tugba Kevser, Bayazit Samet, Askin Ozge, Engin Burhan, Ugurlu Serdal, Sar Mehmet, Serdaroglu Server
Department of Dermatology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey.
Department of Rheumatology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey.
Dermatol Ther. 2020 Nov;33(6):e14477. doi: 10.1111/dth.14477. Epub 2020 Nov 5.
The subacute cutaneous lupus erythematosus (SCLE) is a distinct subtype of lupus erythematosus (LE) representing specific clinical and serological features. Almost 20%-30% of the cases with SCLE are predicted to associated with medications. Thiazide diuretics, terbinafine, antiepileptic, and proton pump inhibitors are the best-known drugs to induce drug-related SCLE. Herein we want to present a 65-year-old female with alendronate induced SCLE, resistant to classical therapies, and respond well to intravenous immunoglobulin (IVIG), suggesting that IVIG could be an alternative treatment in patients resistant to classical treatment protocols.
亚急性皮肤型红斑狼疮（SCLE）是红斑狼疮（LE）的一种独特亚型，具有特定的临床和血清学特征。预计近20%-30%的SCLE病例与药物有关。噻嗪类利尿剂、特比萘芬、抗癫痫药和质子泵抑制剂是最著名的可诱发药物相关SCLE的药物。在此，我们想介绍一位65岁的女性，她因阿仑膦酸钠诱发SCLE，对传统疗法耐药，但对静脉注射免疫球蛋白（IVIG）反应良好，这表明IVIG可能是对传统治疗方案耐药患者的一种替代治疗方法。
